Pembrolizumab-induced Myasthenia Gravis Relapse After Immunosuppressive Therapy

Yuki Oshima; Shintaro Fujii; Kazuhiro Horiuchi

doi:10.2169/internalmedicine.8554-21

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Pembrolizumab-induced Myasthenia Gravis Relapse After Immunosuppressive Therapy

Yuki Oshima, Shintaro Fujii, Kazuhiro Horiuchi

著者情報

キーワード: immunosuppressive, myasthenia gravis, pembrolizumab, an immune-related adverse event, relapse, recurrence

ジャーナルオープンアクセス早期公開

論文ID: 8554-21

DOI https://doi.org/10.2169/internalmedicine.8554-21

この記事には本公開記事があります。

The final version of this article is now available: Vol. 61 (2022), No. 21 pp. 3281-3285

詳細

抄録

Myasthenia gravis (MG) is an immune-related adverse event (irAE), and as an irAE, MG (irAE-MG) generally has a monophasic course, with only a few case reports of irAE-MG flare-ups during the course of the disease. We herein report a case of pembrolizumab-induced MG with relapsing symptoms. irAE-MG is a rare disease that has not yet been fully characterized, and our case shows that MG symptoms may relapse. Therefore, regular follow-up is necessary, even after the symptoms improve with immunosuppressive therapy.

責任著者(Corresponding author)

J-STAGEへの登録はこちら（無料）